Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma
Authors:
- 1 July 2024
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (7) , 979-981
Abstract
This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.Keywords
This publication has 5 references indexed in Scilit:
- Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphomaRadiotherapy and Oncology, 2022
- The Impact of Radiation Timing in Peri-CAR T-Cell Therapy on Local Control for Relapsed/Refractory B-Cell Non-Hodgkin LymphomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2022
- Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?Radiotherapy and Oncology, 2022
- Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaBlood Advances, 2020